52
Participants
Start Date
August 9, 2021
Primary Completion Date
June 18, 2024
Study Completion Date
June 18, 2024
Fruquintinib
Oral VEGFR inhibitor
Tislelizumab
PD-1 inhibitor
Messino Cancer Center, Asheville
Florida Cancer Specialists Panhandle, Tallahassee
Florida Cancer Specialists - East (FCS East), West Palm Beach
Florida Cancer Center North, St. Petersburg
Florida Cancer Specialists - FCS South, Port Charlotte
Tennesse Oncology, Nashville
Vanderbilt Ingram Cancer Center, Nashville
Tennessee Oncology-Chattanooga, Chattanooga
HOC AON Baton Rouge / Sarah Cannon, Baton Rouge
Highlands Oncology, Springdale
Oklahoma University Stephenson Cancer Center, Oklahoma City
The University of Texas MD Anderson Cancer Center, Houston
University of Colorado, Aurora
Mayo Clinic Arizona, Phoenix
Beverly Hills Cancer Center, Beverly Hills
Women and Infants Hospital of Rhode Island, Providence